IN2013MU02905A - - Google Patents

Download PDF

Info

Publication number
IN2013MU02905A
IN2013MU02905A IN2905MU2013A IN2013MU02905A IN 2013MU02905 A IN2013MU02905 A IN 2013MU02905A IN 2905MU2013 A IN2905MU2013 A IN 2905MU2013A IN 2013MU02905 A IN2013MU02905 A IN 2013MU02905A
Authority
IN
India
Prior art keywords
preparation
improved process
relates
ethoxy
phenyl
Prior art date
Application number
Other languages
English (en)
Inventor
Shri Prakash Dhar Dwivedi
Ramesh Chandra Singh
Jagdish Maganlal Patel
Vikas Patel
Vishwadeepak Rama Pati Tripathi
Pranav Jitendra Gangwar
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Priority to US14/916,402 priority Critical patent/US10112898B2/en
Priority to PCT/IN2014/000584 priority patent/WO2015033357A2/en
Priority to IN2905MU2013 priority patent/IN2013MU02905A/en
Publication of IN2013MU02905A publication Critical patent/IN2013MU02905A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333Radicals substituted by oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN2905MU2013 2013-09-06 2014-09-05 IN2013MU02905A (US07794700-20100914-C00152.png)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US14/916,402 US10112898B2 (en) 2013-09-06 2014-09-05 Process for the preparation of saroglitazar pharmaceutical salts
PCT/IN2014/000584 WO2015033357A2 (en) 2013-09-06 2014-09-05 An improved process for the preparation of pyrrole derivatives
IN2905MU2013 IN2013MU02905A (US07794700-20100914-C00152.png) 2013-09-06 2014-09-05

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2905MU2013 IN2013MU02905A (US07794700-20100914-C00152.png) 2013-09-06 2014-09-05

Publications (1)

Publication Number Publication Date
IN2013MU02905A true IN2013MU02905A (US07794700-20100914-C00152.png) 2015-07-03

Family

ID=52023583

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2905MU2013 IN2013MU02905A (US07794700-20100914-C00152.png) 2013-09-06 2014-09-05

Country Status (3)

Country Link
US (1) US10112898B2 (US07794700-20100914-C00152.png)
IN (1) IN2013MU02905A (US07794700-20100914-C00152.png)
WO (1) WO2015033357A2 (US07794700-20100914-C00152.png)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX350611B (es) 2011-01-31 2017-09-11 Cadila Healthcare Ltd Tratamiento para la lipodistrofia.
AU2013387996B2 (en) 2013-04-22 2015-12-10 Cadila Healthcare Limited A novel composition for nonalcoholic fatty liver disease (NAFLD)
MX2015016403A (es) 2013-05-30 2016-04-11 Cadila Healthcare Ltd Proceso para la preparacion de pirroles que tienen actividad hipolipidemica e hipocolesterolemica.
TW201636015A (zh) 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
IN2013MU02470A (US07794700-20100914-C00152.png) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
US10112898B2 (en) 2013-09-06 2018-10-30 Cadila Healthcare Limited Process for the preparation of saroglitazar pharmaceutical salts
WO2017064635A2 (en) 2015-10-14 2017-04-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
ES2894261T3 (es) 2016-12-09 2022-02-14 Cadila Healthcare Ltd Tratamiento de la colangitis biliar primaria
WO2020183379A1 (en) * 2019-03-11 2020-09-17 Cadila Healthcare Limited Novel salts, crystalline forms and premix of hypolipidemic agent
US20220023262A1 (en) * 2020-07-24 2022-01-27 Cadila Healthcare Limited Composition comprising high purity pyrrole derivative and method for preparation thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
PL174610B1 (pl) 1992-07-03 1998-08-31 Smithkline Beecham Plc Nowe związki heterocykliczne
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
US5387613A (en) 1993-07-23 1995-02-07 Ribogene, Inc. Treatment of tachyarrhythmias of supraventricular origin
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
BR9508468A (pt) 1994-07-29 1997-11-25 Smithkline Beecham Plc Composto processo para a preparação do mesmo composição farmacéutica processos para o tratamento e/ou profilaxia de hiperglicemia em um mamifero humano ou não humano e para o tratamento de hiperlípidemia hipertensão doença cardiovascular alguns distúrbios de alimentação o tratamento e/ou profilaxia de doença renal a prevenção revers o estabilização ou retardo da progressão de microalbuminuria em um mamifero humano ou não humano uso do composto e composto intermediário
DK0826688T3 (da) 1995-04-28 2001-10-22 Daiichi Seiyaku Co Pentacykliske forbindelser
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
CN1280574A (zh) 1997-10-27 2001-01-17 雷迪研究基金会 新的杂环化合物及其在医药中的应用、它们的制备方法和含有它们的药物组合物
WO1999020614A1 (en) 1998-05-27 1999-04-29 Dr. Reddy's Research Foundation Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
WO1999008501A2 (en) 1998-04-23 1999-02-25 Dr. Reddy's Research Foundation New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
WO2000023445A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
EP1123269A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
EP1123297A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
MEP32408A (en) 2000-01-19 2010-10-10 Cadila Healthcare Ltd Compounds having hypolipedemic and hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
WO2002024625A2 (en) 2000-09-22 2002-03-28 Dr. Reddy's Research Foundation Process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives
US6514995B1 (en) 2000-09-25 2003-02-04 Advanced Research And Technology Institute, Inc. Enediyne compounds and methods related thereto
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6987123B2 (en) * 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2005031335A1 (ja) 2003-09-26 2005-04-07 Mitsubishi Rayon Co., Ltd. 電気泳動装置および電気泳動法並びにそれを用いた生体関連物質の検出方法
AU2004318013B8 (en) 2004-03-15 2011-10-06 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP2018157A2 (en) 2006-04-26 2009-01-28 Astron Research Limited Controlled release formulation comprising anti-epileptic drugs
EP2641596B1 (en) 2009-11-26 2018-05-02 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
CA2814194A1 (en) 2010-10-12 2012-04-19 The Johns Hopkins University Antitussive compositions comprising memantine
MX350611B (es) 2011-01-31 2017-09-11 Cadila Healthcare Ltd Tratamiento para la lipodistrofia.
AU2013387996B2 (en) 2013-04-22 2015-12-10 Cadila Healthcare Limited A novel composition for nonalcoholic fatty liver disease (NAFLD)
MX2015016403A (es) 2013-05-30 2016-04-11 Cadila Healthcare Ltd Proceso para la preparacion de pirroles que tienen actividad hipolipidemica e hipocolesterolemica.
TW201636015A (zh) 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
IN2013MU02470A (US07794700-20100914-C00152.png) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
IN2013MU02828A (US07794700-20100914-C00152.png) 2013-08-29 2015-07-03 Cadila Healthcare Ltd
US10112898B2 (en) 2013-09-06 2018-10-30 Cadila Healthcare Limited Process for the preparation of saroglitazar pharmaceutical salts

Also Published As

Publication number Publication date
US20160194280A1 (en) 2016-07-07
US10112898B2 (en) 2018-10-30
WO2015033357A3 (en) 2015-05-07
WO2015033357A2 (en) 2015-03-12

Similar Documents

Publication Publication Date Title
IN2013MU02905A (US07794700-20100914-C00152.png)
PH12020551628A1 (en) A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
MY181898A (en) Heterocyclic compounds and uses thereof
MY150542A (en) Cmet inhibitors
MX2012004114A (es) Compuestos heterociclicos utiles como inhibidores de proteina cinasa-1 dependiente de 3-fosfoinositido (pdk1).
SMT201300098B (it) Forme solide di N-(4-(7-azabiciclo[2.2.1]eptan-7-il)-2-(trifluorometil)fenil-4-osso-5-trifluorometil)-1,4-diidrochinolina-3-carbossammide
CL2014001765A1 (es) Proceso para la fabricacion de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina.
TN2011000673A1 (en) Bace inhibitors
WO2013098833A3 (en) Processes and intermediates for preparing rivaroxaban
PT2470546E (pt) Compostos de hexa-hidrooxazinopteridina para serem utilizados como inibidores de mtor
UY34480A (es) Compuestos de 2-(fenilo sustituido)-ciclopentan-1,3-diona y derivados de los mismos, composiciones y métodos para controlar malezas.
MX353578B (es) Dihidrodiazpinocarbazolonas tetra o penta-ciclicas fusionadas como inhibidores de poli (adp-ribosa) polimerasa (parp).
HUE041725T2 (hu) (S)-1-(2-hidroxietil)-4-metil-N-[4-(metilszulfonil)fenil]-5-[2-(trifluormetil)fenil]-1H-pirrol-3-karboxamid kristálya
MX2015017156A (es) Inhibidores de bace.
EP3666770A4 (en) NEW HETEROCYCLIC COMPOUNDS AS CDK8 / 19 INHIBITORS
CL2011003009A1 (es) Proceso de preparacion de compuestos derivados de 4-fenil-3,5-(tio)piranodionas; compuesto intermediario; y preparacion de dicho intermediario.
MX2018007219A (es) Metodos para preparacion de compuestos heterociclicos de 1,3-benzodioxol.
MX364207B (es) Inhibidores de agrecanasa.
MX2016016378A (es) Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
MX2011006560A (es) Derivados heterociclicos fucionados con oxadiazola utiles para el tratamiento de esclerosis multiple.
IN2013MU03862A (US07794700-20100914-C00152.png)
EA201491227A1 (ru) Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2
WO2013175499A3 (en) Process for the preparation of 5-(4-[4-(5-cyano-1 h-indol-3-yl)butyl]piperazin-1 -yl)benzofuran-2-carboxamide and intermediates thereof, polymorphic forms thereof
PH12018502246A1 (en) Substituted fused pyrimidinone compounds
IN2013MU00665A (US07794700-20100914-C00152.png)